Taketoshi Furugori
Daiichi Sankyo (Germany)(DE)Daiichi Sankyo (United Kingdom)(GB)Daiichi Sankyo (United States)(US)
Publications by Year
Research Areas
Antiplatelet Therapy and Cardiovascular Diseases, Atrial Fibrillation Management and Outcomes, Blood Coagulation and Thrombosis Mechanisms, Blood Pressure and Hypertension Studies, Hormonal Regulation and Hypertension
Most-Cited Works
- → Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element(2004)70 cited
- → Rational Design and Evaluation of New Lead Compound Structures for Selective βARK1 Inhibitors(2002)42 cited
- → Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives(2004)19 cited
- → P2Y<sub>12</sub> Reaction Units With Prasugrel in Acute Large Artery Atherosclerosis and Transient Ischemic Attack: An Open-Label Randomized Controlled Study, ACUTE-PRAS(2025)2 cited
- → Differences in P2Y<sub>12</sub> Reaction Units Between Prasugrel and Clopidogrel by Ischemic Cerebrovascular Disease Subtypes ― Subanalysis From ACUTE-PRAS ―(2025)1 cited
- → Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study(2025)